Literature DB >> 18219453

Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe in lung cancer drug-resistance cells.

Yong Cao1, Qing-hua Xia, Hua Meng, An-pu Zhong.   

Abstract

OBJECTIVE: To explore the pharmacologic effects of Chinese medicine Bushen Huayu Jiedu Compound Recipe (BSHYJDR) in drug-resistance cells of lung cancer.
METHODS: Human lung adenocarcinoma A549/DDP cell strain was selected, serum pharmacology and flow cytometer (FCM) method were adopted, S180 tumor-bearing mice and normal mice were given, through gastrogavage, different doses of a decocted concentration of BSHYJDR. Serum from the abdominal aorta was taken to observe the effect of drug-serum on cisplatin (DDP) concentration, free Ca2+ concentration and the expression of lung drug-resistance protein LRP-56 in A549/DDP cells.
RESULTS: Compared with the drug-resistance group, the intracellular DDP concentration in the group taking a high dose and the normal group of Chinese medicine showed significant difference (P<0.05), while no significant difference was found in the low-dose group (P>0.05). Compared with the drug-resistance group, the Ca2+ concentration in cells and the expression of LRP in lung cancer drug-resistance cells A549/DDP of the high-dose group, the low-dose group and the normal group of Chinese medicine were significantly different (all P<0.01), the LRP expression of the normal group was obviously higher than that of the drug-resistance group (P<0.05).
CONCLUSION: It was indicated that serum containing Chinese medicine BSHYJDR in the tumor-bearing mice and the normal mice had certainly different, tumor-bearing mice serum containing could improve drug concentration in lung cancer drug-resistance cells, prevent the inflow and release of Ca2+, and inhibit the expression of the drug-resistance gene in the lung cancer drug-resistance cells, which might be the mechanism of BSHYJDR in enhancing the efficacy in reversing and inhibiting tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18219453     DOI: 10.1007/s11655-007-9004-4

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  8 in total

1.  Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer.

Authors:  T Oguri; T Isobe; T Suzuki; K Nishio; Y Fujiwara; O Katoh; M Yamakido
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

2.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

Authors:  R J Scheper; H J Broxterman; G L Scheffer; P Kaaijk; W S Dalton; T H van Heijningen; C K van Kalken; M L Slovak; E G de Vries; P van der Valk
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

Review 3.  Biology of the multidrug resistance-associated protein, MRP.

Authors:  D W Loe; R G Deeley; S P Cole
Journal:  Eur J Cancer       Date:  1996-06       Impact factor: 9.162

4.  [Clinical significance of the expression of lung resistance protein in non-small cell lung carcinomas].

Authors:  M Lü; J Wang; X Yi
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2001-08

5.  Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs.

Authors:  W Berger; L Elbling; M Micksche
Journal:  Int J Cancer       Date:  2000-10-15       Impact factor: 7.396

6.  Lung resistance-related protein gene expression and drug sensitivity in human gastric and lung cancer cells.

Authors:  K Ikeda; M Oka; F Narasaki; M Fukuda; T Nakamura; S Nagashima; K Terashi; S Sato; S Kawabata; Y Mizuta; H Soda; S Kohno
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

7.  Effect of KN-62, Ca2+/calmodulin-dependent protein kinase II inhibitor, on adriamycin resistance of human ovarian cancer cells.

Authors:  N H Obata; K Okazaki; O Maeda; F Kikkawa; Y Tomoda; H Hidaka
Journal:  Biochem Biophys Res Commun       Date:  1995-10-13       Impact factor: 3.575

8.  Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.

Authors:  P Nygren; R Larsson; A Gruber; C Peterson; J Bergh
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

  8 in total
  3 in total

1.  Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines.

Authors:  Stella Chai; Kenneth Kw To; Ge Lin
Journal:  Chin Med       Date:  2010-07-25       Impact factor: 5.455

2.  Combining ZHENG Theory and High-Throughput Expression Data to Predict New Effects of Chinese Herbal Formulae.

Authors:  Shuhao Yu; Zhizhong Guo; Yan Guan; Yi-Yu Lu; Pei Hao; Yixue Li; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-14       Impact factor: 2.629

3.  Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.

Authors:  Wendian Zhang; Hechao Zhou; Ying Yu; Jingjing Li; Haiwen Li; Danxian Jiang; Zihong Chen; Donghong Yang; Zumin Xu; Zhonghua Yu
Journal:  Onco Targets Ther       Date:  2016-06-02       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.